HSBC raises Bristol-Myers Squibb price target to $65
HSBC increased its price target on Bristol-Myers Squibb (BMY) to $65, citing a Phase II update in the company’s experimental cell therapy that met a primary endpoint.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.